Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase II of zevorcabtagene autoleucel (fully human BCMA CAR T) in relapsed/refractory myeloma finds ORR 92.2% (68.6% sCR); 44.1% progression-free at 20.3 mos; CRS in 90.2% (mostly grade 1/2); 2 patients with ICANS (both grade 1).”
Title: Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Authors: Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Daijing Yuan, Huamao Wang, Zonghai Li
You can read the Full Article in Experimental Hematology and Oncology.
You can find more posts featuring Robert Orlowski on OncoDaily.
